Estonya - Estonca - Ravimiamet

meridian medical technologies inc. - epinefriin (adrenaliin) - süstelahus pen-süstlis - 0,3mg 0.3ml 0.3ml 1tk

Estonya - Estonca - Ravimiamet

meridian medical technologies, inc. - morfiin - süstelahus pen-süstlis - 10mg 0.7ml 0.7ml 1tk

Estonya - Estonca - Ravimiamet

map medical technologies oy - tehneetsium(99m tc)pertehnetaat - radionukliidgeneraator - 24gbq 1tk

Estonya - Estonca - Ravimiamet

map medical technologies oy - fluorokoliin (18f) - süstelahus - 2tk

Estonya - Estonca - Ravimiamet

map medical technologies oy - naatriumjodiid (131i) - pehmekapsel - 1tk

Estonya - Estonca - Ravimiamet

carlsbad technology, inc. - famotidiin - tablett - 20mg 100tk

Estonya - Estonca - Ravimiamet

map medical technologies oy - 18f-dcfpyl - süstelahus - 1tk

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaktsiinid - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratoorsed süntsüütilised viirusinfektsioonid - vaktsiinid - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Estonya - Estonca - Ravimiamet

septodont - mepivakaiin - süstelahus - 30mg 1ml 1.7ml 50tk; 30mg 1ml 2.2ml 50tk